A Review of the Potential Therapeutic Benefits of Quercetin for Uterine-Related Conditions

Leone MA, Michael A. Leone, Georgia Kurman, Madeline Bright, Peter K. Gregersen, Christine N. Metz
Biomedicines · 2026 · vol. 14(6) , pp. 1205 · doi:10.3390/biomedicines14061205 · PMID:42351637 · W7162572125
Review OA: gold CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This review examines quercetin's anti-inflammatory, antioxidant, and other properties, evaluating preclinical and clinical evidence for its potential benefits in six uterine conditions, while noting a lack of robust human data.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Quercetin is a naturally occurring flavonoid found in fruits, vegetables, and teas that is widely available as a dietary supplement. Numerous studies have investigated quercetin's therapeutic potential across a broad range of diseases and conditions. Collectively, these studies reveal its anti-inflammatory, antioxidant, anti-proliferative, anti-cancer, anti-fibrotic, antibacterial, endocrine-modulating, and senolytic properties, establishing quercetin as a polypharmacologic agent with diverse biological activities. This review describes quercetin's biochemical properties, bioavailability, and proposed mechanisms of action. It highlights the unique characteristics of the human uterus vs. other species and evaluates published evidence from pre-clinical and clinical studies supporting quercetin's pleiotropic effects and potential therapeutic benefits for six uterine-related conditions: endometrial cancer, endometriosis, adenomyosis, uterine infections, uterine fibroids, and polycystic ovary syndrome (PCOS). The findings support that quercetin targets multiple endometrial and other uterine cell types and may attenuate key pathological processes relevant to uterine disease. However, robust human clinical evidence supporting quercetin's efficacy is generally lacking. Critical knowledge gaps and translational barriers to advancing quercetin from a 'promising preclinical candidate' into an 'evidence-based therapeutic' for improving uterine health are discussed.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (100)

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
openalex
last seen: 2026-08-26T06:01:51.998721+00:00
pubmed
last seen: 2026-10-11T06:07:50.393129+00:00
License: CC0 · commercial use OK